Chengdu Bright Eye Hospital Co. Ltd. (301239) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Chengdu Bright Eye Hospital Co. Ltd. stock ¥27.43, price ¥36.01, that is 23.8% below the price, quality 53 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
52‑month range ¥28.56 – ¥135.69 · fair‑value band ¥20.14 – ¥34.74 · the ¥36.01 price screens above the ¥27.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Chengdu Bright Eye Hospital Co. in your weekly email
Every Wednesday you see whether Chengdu Bright Eye Hospital Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bright Eye Hospital Group Co., Ltd., a specialized chain medical institution company, engages in the provision of ophthalmic general medical services in China.
Show moreShow less
Its ophthalmology institutions provide diagnosis, treatment, health care, medical optometry, glasses, and other general ophthalmic medical services for patients with ophthalmic diseases in the areas of refractive surgery, cataract, ophthalmology, fundus disease, glaucoma, strabismus and pediatric ophthalmology, tear duct, cornea disease, orbital disease, ocular trauma, medical optometry, and other general ophthalmology diagnosis and treatment items.
The company was formerly known as Chengdu Bright Eye Hospital Group Co., Ltd. and changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025. The company was founded in 2005 and is headquartered in Chengdu, China.
Stock analysis
Chengdu Bright Eye Hospital Co. Ltd. (301239) currently trades at ¥36.01, while our model-based Fair Value estimate is ¥27.43, 24% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥31.90 per share, and 5 of the 14 models we run sit above the ¥36.01 price.
Bear case: the Earnings-Based group reads lowest at ¥6.79, and 9 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥20.14 (bear) to ¥34.74 (bull), the price of ¥36.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Chengdu Bright Eye Hospital Co. Ltd. reported revenue of 2.8B CNY in FY2025 versus 1.7B CNY in FY2021, a compound +13.1%/yr. Reported net income was −60.9M CNY in FY2025.
Key figures
Market cap 5.4B CNY (≈ $808M) Small · P/E ratio 73.5 · P/S ratio 1.77 · EPS (TTM) ¥0.4900 · Dividend yield 1.7% · Net margin 2.4% · Return on equity 3.9% · Return on assets (EBIT) 4.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −24%, 301239 screens richer than that median.
Fair Value models
Bear¥20.14Fair Value ¥27.43Bull¥34.74
Price ¥36.01 · Downside -23.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF¥23.67¥39.22¥62.9679
Growth DCF¥23.42¥37.38¥57.5877
Owner Earnings¥8.92¥14.91¥24.0575
All 14 models by family
DCF Models
FCF DCF¥23.67¥39.22¥62.9679
Owner Earnings¥8.92¥14.91¥24.0575
5Y Revenue Exit¥13.81¥20.81¥29.7172
5Y EBITDA Exit¥27.68¥48.91¥75.1774
10Y Revenue Exit¥17.07¥24.57¥34.9667
10Y EBITDA Exit¥25.82¥43.54¥69.7767
Earnings-Based
EPV¥5.91¥6.79¥7.5371
Multiples
EV/EBIT¥11.19¥15.24¥19.3066
EV/EBITDA¥32.43¥43.56¥54.6967
EV/Revenue¥7.71¥11.43¥15.1553
Asset-Based
NCAV (Graham)¥5.31¥7.11¥10.6154
Growth DCF
Growth DCF¥23.42¥37.38¥57.5877
Rev-Margin DCF¥13.81¥20.98¥30.1472
Economic Profit
ROIC Compounder¥5.91¥6.79¥7.5372
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.3% (2019) → 5.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +7.3% a year for the price.
Compare Chengdu Bright Eye Hospital Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−23.8% · Below median
Profitability
Return on equity (12 months)3.9% · Below median
Return on assets−1.3% · Bottom 25%
Net margin (12 months)2.4% · Below median
Operating margin (12 months)13.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)13.8% · Above median
Dividend yield (12 months)1.7% · Below median
Balance sheet
Debt / equity0.19× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)73.5× · Priciest 25%
P/B2.64× · Pricier than median
P/S (12 months)1.77× · Pricier than median
Price / free cash flow (fiscal year)16.9× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Chengdu Bright Eye Hospital Co. Ltd. (301239) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥27.43 versus a price of ¥36.01, about 24% lower (overvalued).
What is the fair value of 301239?
Our model-based fair value for Chengdu Bright Eye Hospital Co. Ltd. is ¥27.43 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥36.01.
What is the quality score of 301239?
Chengdu Bright Eye Hospital Co. Ltd. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Our model-based price target is the fair value of ¥27.43 (as of Nov 5, 2026) from 14 valuation models. Cautious scenario ¥20.14, optimistic scenario ¥34.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Chengdu Bright Eye Hospital Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥27.43, about 24% lower versus a price of ¥36.01 (overvalued). Cautious scenario ¥20.14, optimistic scenario ¥34.74. The calculation is refreshed regularly with new filings.
What is the revenue of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Chengdu Bright Eye Hospital Co. Ltd. reported trailing-twelve-month revenue of about 3.0B CNY (latest available figure, as of Nov 5, 2026).
Does Chengdu Bright Eye Hospital Co. Ltd. pay a dividend?
Chengdu Bright Eye Hospital Co. Ltd. currently shows a dividend yield of 1.67% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Chengdu Bright Eye Hospital Co. Ltd. (301239) and when is the ex-dividend date?
Chengdu Bright Eye Hospital Co. Ltd. pays a dividend of ¥0.6 per share a year, a dividend yield of 1.7%. The last ex-dividend date was Sep 11, 2026. The payout ratio is 122% of earnings. Free cash flow covers the dividend 3.55 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Chengdu Bright Eye Hospital Co. Ltd. (301239)?
For today's price to be fair in a discounted-cash-flow model, Chengdu Bright Eye Hospital Co. Ltd. would have to grow free cash flow by +9.1 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 301239 use?
Our models discount Chengdu Bright Eye Hospital Co. Ltd. at 10.6 %: a base by market capitalisation (small), damped by beta 0.56, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chengdu Bright Eye Hospital Co. Ltd. that is +9.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Chengdu Bright Eye Hospital Co. Ltd. (301239) delivered so far?
Over the past 5 years revenue at Chengdu Bright Eye Hospital Co. Ltd. grew +15.5 % a year. The price currently implies free-cash-flow growth of +9.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chengdu Bright Eye Hospital Co. Ltd. (301239) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Chengdu Bright Eye Hospital Co. Ltd. (+9.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The free-cash-flow yield on the price is 5.91 %: that much free cash flow Chengdu Bright Eye Hospital Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chengdu Bright Eye Hospital Co. Ltd. it is ¥27.43 per share (as of Nov 5, 2026), against a price of ¥36.01. It is the blended result of 14 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Chengdu Bright Eye Hospital Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 301239 trades above its calculated fair value: price ¥36.01, fair value ¥27.43, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301239?
No. The price is what the market pays today (¥36.01); the fair value is what the company's own numbers justify (¥27.43). For Chengdu Bright Eye Hospital Co. Ltd. the two are ¥8.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chengdu Bright Eye Hospital Co. Ltd. worth?
The market values Chengdu Bright Eye Hospital Co. Ltd. at about 5.4B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥36.01; our models calculate a fair value of ¥27.43 per share.
What do the bullish and bearish scenarios say about 301239?
Our models span a range for Chengdu Bright Eye Hospital Co. Ltd.: cautious scenario ¥20.14, base ¥27.43, optimistic ¥34.74 per share (as of Nov 5, 2026, price ¥36.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301239?
Chengdu Bright Eye Hospital Co. Ltd. trades at a price-to-earnings ratio of 73.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥27.43 is built from several models across several years. Other multiples: P/B 2.6, P/S 1.8, EV/EBITDA 12.8.
How solid is the balance sheet of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Balance-sheet figures for Chengdu Bright Eye Hospital Co. Ltd. (as of Nov 5, 2026): return on equity 3.9%, debt of 0.19 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 301239 from its 52-week high?
Chengdu Bright Eye Hospital Co. Ltd. trades at ¥36.01, about 22% below its 52-week high of ¥46.39 and 25% above the low of ¥28.82 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥27.43 is for.
Which stocks are comparable to Chengdu Bright Eye Hospital Co. Ltd.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chengdu Bright Eye Hospital Co. Ltd. stock attractive at the current price?
The data as of Nov 5, 2026: price ¥36.01, calculated fair value ¥27.43 (−24%), Quality Score 53/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301239 calculated?
We run Chengdu Bright Eye Hospital Co. Ltd. through 14 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of ¥27.43 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Chengdu Bright Eye Hospital Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The closing price on Nov 6, 2026 was ¥36.01. Our model-based fair value is ¥27.43, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chengdu Bright Eye Hospital Co. Ltd. right now?
The price sits above even our optimistic bull case (¥34.74). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Chengdu Bright Eye Hospital Co. Ltd.
How large is the market capitalisation of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The market capitalisation of Chengdu Bright Eye Hospital Co. Ltd. is 5.4B CNY (≈ $808M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The price-to-sales ratio of Chengdu Bright Eye Hospital Co. Ltd. is 1.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Earnings per share at Chengdu Bright Eye Hospital Co. Ltd. are ¥0.4900 (price ÷ EPS = P/E 73.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The dividend yield of Chengdu Bright Eye Hospital Co. Ltd. is 1.7% (payout 122%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The net margin of Chengdu Bright Eye Hospital Co. Ltd. is 2.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The return on equity (ROE) of Chengdu Bright Eye Hospital Co. Ltd. is 3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
On an EBIT basis the return on assets of Chengdu Bright Eye Hospital Co. Ltd. is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chengdu Bright Eye Hospital Co. Ltd. (301239)?
The operating margin of Chengdu Bright Eye Hospital Co. Ltd. is 13.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Revenue at Chengdu Bright Eye Hospital Co. Ltd. is growing +13.8% versus a year earlier (3y avg +17.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chengdu Bright Eye Hospital Co. Ltd. (301239)?
Earnings per share at Chengdu Bright Eye Hospital Co. Ltd. are growing +37.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Chengdu Bright Eye Hospital Co. Ltd. (301239) carry?
The net debt of Chengdu Bright Eye Hospital Co. Ltd. is 144M CNY (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Chengdu Bright Eye Hospital Co. Ltd. in the live analysis
One click puts Chengdu Bright Eye Hospital Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026